Drug intelligence / Profile preview

Yizhi Tongluo Fang

Development stage: Unknown
Lead developer: Beijing Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Yizhi Tongluo Fang is a Traditional Chinese Medicine (TCM) herbal formula developed by the Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University. It is primarily indicated for the treatment of mild cognitive impairment (MCI), specifically targeting patients with the TCM syndrome of kidney deficiency and blood stasis. The formula is designed to tonify the kidney and resolve blood stasis to improve cognitive function and memory. In clinical research, it is being evaluated as a standalone therapy and in combination with cognitive digital therapy (a form of digital therapeutic intervention) to assess its efficacy in improving cognitive outcomes in MCI patients.

Other names: Yizhi Tongluo prescriptionYizhi Tongluo decoction

Beyond the preview

Go deeper on Yizhi Tongluo Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yizhi Tongluo Fang.

Explore the full profile